empagliflozin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on glycated haemoglobin (HbA1c)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“In comparison with the control group, empagliflozin treatment can attenuate HOMA-IR levels, the statistical difference was significant (MD: −0.45, 95% CI: −0.90 to 0.00, p = 0.05, I2 = 0%), but there were no significant diversity in HbA1c (MD: −0.10, 95% CI: −0.60 to −0.40, p = 0.70, I2 = 42.79%), FBS (MD: −1.21, 95% CI: −4.98 to 2.55, p = 0.53, I2 = 0%), insulin (MD: 3.63, 95% CI: −7.64 to 14.90, p = 0.53, I2 = 90%), and HOMA2-IR (MD: −0.12, 95% CI: −0.45 to 0.20, p = 0.46, I2 = 0%).”
Quoted verbatim from Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Population
- Patients with NAFLD, pooled across randomized trials of empagliflozin 20 to 24 weeks; control arms were mostly placebo with one glimepiride arm
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.2022PMID:35282455Permalink
Keep reading
- Everything the graph holds on empagliflozin
- Every compound studied against Glycated haemoglobin (HbA1c)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PR74JRWHCZRG4M06HBWQHX